Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 264

Drug Profile

GB 264

Alternative Names: Claudin 18.2/CD3 bispecific antibody - Antibody Therapeutics; Claudin 18.2/CD3 BsAb - Antibody Therapeutics; Claudin 18.2xCD3 bispecific antibody - Genor Biopharma; GB-264

Latest Information Update: 21 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Developer Antibody Studio; Antibody Therapeutics; Genor Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 10 Apr 2021 Preclinical trials in Pancreatic cancer in China (Parenteral) (Genor Biopharma website, March 2021)
  • 10 Apr 2021 Preclinical trials in Pancreatic cancer in USA (Parenteral)
  • 10 Apr 2021 Pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top